STOCK TITAN

Apimeds to issue 350K shares for Apitox rights

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Apimeds Pharmaceuticals US, Inc. (APUS) amended its agreement with FreeT Inc. on November 12, 2026, to clarify consideration for certain Apitox-related rights. Apimeds is to issue FreeT 350,000 shares of common stock by December 1, 2026 as the initial payment. The issuance is unregistered and relies on the Securities Act exemption under Section 4(a)(2).

Apimeds and FreeT shall jointly appoint an independent valuer within 60 days to determine the rights’ fair value. If that valuation exceeds the initial payment, Apimeds must pay the additional amount within 30 days after valuation completion, in cash, common stock, or a combination at its discretion.

Filing Explained

The filing says FreeT irrevocably assigned, transferred and delivered the specified Apitox rights to Apimeds under the August 19 agreement, describing the rights transfer as complete; this amendment sets consideration for those rights.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 3.02 Unregistered Sales of Equity Securities Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Initial payment 350,000 shares of common stock To be issued to FreeT by December 1, 2026, for the Assigned Rights
Valuer appointment period 60 days From November 12, 2026, for Apimeds and FreeT to jointly appoint an independent third-party valuer
Additional payment period 30 days After completion of the valuation, if it exceeds the initial payment
Assigned Rights technical
"certain Apitox-related rights (the “Assigned Rights”)"
fair value financial
"determine the fair value of the Assigned Rights"
Fair value is an estimate of what an asset or company is really worth today, derived from expected future earnings, comparable market prices and other relevant facts—like agreeing a price for a used car after checking mileage, condition and similar listings. Investors use fair value to decide whether a stock looks overpriced or undervalued, which helps guide buy, hold or sell decisions and sets expectations for potential returns and risk.
Section 4(a)(2) regulatory
"exemption from registration provided by Section 4(a)(2)"
Section 4(a)(2) is a part of U.S. securities laws that allows companies to sell their stock directly to certain investors without registering the sale with regulators. This process is often used for private placements, making it easier and faster for companies to raise money from knowledgeable or institutional investors. It matters to investors because it provides an alternative way to buy shares, often with fewer disclosures and lower costs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many APUS shares will Apimeds issue to FreeT?

Apimeds is to issue 350,000 shares of common stock by December 1, 2026 as the initial payment for the Assigned Rights.

What happens if the Apitox rights valuation exceeds the initial payment?

Apimeds must pay the additional amount within 30 days after the valuation is completed, in cash, common stock, or a combination at its discretion.

When will Apimeds and FreeT arrange the Apitox rights valuation?

They shall jointly appoint an independent third-party valuer within 60 days of November 12, 2026. The valuer is to have recognized standing and experience valuing pharmaceutical and life-sciences rights.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001894525 0001894525 2026-11-12 2026-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): November 12, 2026

 

Apimeds Pharmaceuticals US, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-42545   85-1099700
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (I.R.S. Employer
Identification Number)

 

100 Matawan Rd, Suite 325

Matawan, New Jersey

  07747
(Address of principal executive offices)   (Zip code)

 

Registrant’s telephone number, including area code: (848) 201-5010

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.01 per share   APUS   NYSE American LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

Amendment

 

As previously announced, on August 19, 2026, Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “Company”), entered into an Assignment and Transfer Agreement of Certain Apitox Rights (the “Assignment Agreement”) with FreeT Inc., a company organized under the laws of the Republic of Korea (“FreeT”). FreeT is the successor to CNP Roen Co., Ltd., which subsequently changed its corporate name to Inscobee Co., Ltd. and is currently known as FreeT Inc.

 

Pursuant to the Assignment Agreement, FreeT irrevocably assigned, transferred, conveyed and delivered to the Company all of FreeT’s right, title and interest in and to certain Apitox-related rights (the “Assigned Rights”) that were originally acquired by CNP Roen Co., Ltd. under an Apitox Rights Transfer Agreement dated June 16, 2015 (the “2015 Agreement”). On November 12, 2026, the Company and FreeT entered into that certain Amendment No. 1 to the Assignment and Transfer Agreement of Certain Apitox Rights (the “Amendment”) to clarify the consideration paid to FreeT in connection with the Assigned Rights under Article 7 of the Assignment Agreement. The Assignment Agreement and the Amendment is governed by the laws of the Republic of Korea, with exclusive jurisdiction in the Seoul Central District Court.

 

Valuation and Consideration

 

Pursuant to the Amendment, the Company shall issue to FreeT 350,000 shares of common stock of the Company no later than December 1, 2026 (the “Initial Payment”). Within sixty days of the date of the Amendment, the Company and FreeT shall jointly appoint an independent third-party valuer of recognized standing with experience in the valuation of pharmaceutical and life-sciences rights to determine the fair value of the Assigned Rights (the “Valuation”). If the Valuation exceeds the Initial Payment, the Company shall pay the additional amount to FreeT within thirty days of the completion of the Valuation, in cash, common stock, or a combination of cash and common stock at the discretion of the Company.

 

The foregoing summary of the Amendment does not purport to be a complete description and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference.

 

Item 3.02 Unregistered Sales of Equity Securities.

  

The disclosure set forth above in Item 1.01 of this Current Report on Form 8-K in the sections titled “Valuation and Consideration” is incorporated into this Item 3.02 by reference. The issuance of the Initial Payment have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
10.1   Amendment No. 1 to Assignment and Transfer Agreement of Certain Apitox Rights, dated November 12, 2026, by and between Apimeds Pharmaceuticals US, Inc. and FreeT Inc.
104   Cover Page Interactive Data File (embedded within the inline XBRL document)

 

1

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Apimeds Pharmaceuticals US, Inc.
   
Date: November 20, 2026 By: /s/ Dr. Vin Menon
  Name:  Dr. Vin Menon
  Title: Co-Chief Executive Officer

 

  By: /s/ SungJoon Chae
  Name:  SungJoon Chae
  Title: Co-Chief Executive Officer

 

2

 

 

Filing Exhibits & Attachments

4 documents

Keep reading